{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:26:08Z","timestamp":1768411568040,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jhep.2019.05.021","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:14:40Z","timestamp":1559686480000},"page":"498-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A pilot study of safety and efficacy of HCV retreatment with sofosbuvir\/velpatasvir\/voxilaprevir in patients with or without HIV (RESOLVE STUDY)"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-514X","authenticated-orcid":false,"given":"Eleanor","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Covert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-9220","authenticated-orcid":false,"given":"Lydia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Husson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-4672","authenticated-orcid":false,"given":"Joel","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-4871","authenticated-orcid":false,"given":"Elana","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kattakuzhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Masur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.05.021_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-med-052915-015720","article-title":"Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs","volume":"68","author":"Naggie","year":"2017","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.jhep.2019.05.021_b0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3851\/IMP3061","article-title":"Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials","volume":"22","author":"Arias","year":"2017","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.jhep.2019.05.021_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jvh.12796","article-title":"Treatment of hepatitis C with 8 weeks of ledipasvir\/sofosbuvir: highly effective in a predominantly black male patient population","volume":"25","author":"Tang","year":"2018","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jhep.2019.05.021_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jvh.12611","article-title":"Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study","volume":"24","author":"Tapper","year":"2017","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jhep.2019.05.021_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.jhep.2019.05.021_b0030","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.05.021_b0035","unstructured":"FDA. FDA approves Vosevi for Hepatitis C. www.fda.gov; 2017."},{"key":"10.1016\/j.jhep.2019.05.021_b0040","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients","author":"Mathur","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.05.021_b0045","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Unique Populations \u2013 Patients with HIV\/HCV Coinfection. May 24, 2018 2018. https:\/\/www.hcvguidelines.org\/unique-populations\/hiv-hcv."},{"issue":"3","key":"10.1016\/j.jhep.2019.05.021_b0050","doi-asserted-by":"crossref","first-page":"ofx158","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus\/human immunodeficiency virus coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2019.05.021_b0055","doi-asserted-by":"crossref","DOI":"10.5009\/gnl18004","article-title":"Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C\/HIV coinfection in a community care setting","author":"Gayam","year":"2018","journal-title":"Gut Liver"},{"issue":"4","key":"10.1016\/j.jhep.2019.05.021_b0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"Milazzo","year":"2017","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.jhep.2019.05.021_b0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/civ874","article-title":"Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens","volume":"62","author":"Wilson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.05.021_b0070","unstructured":"Tivicay (dolutegravir) [package insert]. Gilead Sciences, Inc, Foster City, CA. 2013."},{"issue":"8","key":"10.1016\/j.jhep.2019.05.021_b0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/17425255.2017.1351942","article-title":"Drug interactions in HIV-infected patients treated for hepatitis C","volume":"13","author":"Soriano","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.jhep.2019.05.021_b0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2019.05.021_b0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jhep.2018.10.031","article-title":"HCV genotype 1\u20136 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape","volume":"70","author":"Pham","year":"2019","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:36:45Z","timestamp":1759174605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819303071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0168827819303071"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study of safety and efficacy of HCV retreatment with sofosbuvir\/velpatasvir\/voxilaprevir in patients with or without HIV (RESOLVE STUDY)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}